H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Atossa Therapeutics (ATOS – Research Report) today and set a price target of $7.00.
Emily Bodnar’s rating is based on Atossa Therapeutics’ strategic focus on the development of Z-endoxifen for metastatic breast cancer (mBC). The company has prioritized this area due to the promising clinical efficacy Z-endoxifen has shown in previous trials, particularly in patients who have experienced aromatase inhibitors, fulvestrant, or tamoxifen, as well as those naive to CDK4/6 inhibitors. This strategic direction could potentially lead to a more streamlined FDA approval process, given the smaller Phase 3 program compared to other settings.
Furthermore, Atossa’s ongoing EVANGELINE trial has demonstrated significant tumor suppression in premenopausal ER+/HER2- breast cancer patients, with high Ki-67 response rates. The trial’s amendments to address gynecological events and the planned updates on patient enrollment and data further support the potential of Z-endoxifen. These factors, combined with the possibility of differentiating Z-endoxifen in a competitive landscape, underpin Bodnar’s Buy rating for Atossa Therapeutics.